---
title: "Takeda Pharmaceutical Company Limited (TAK.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/TAK.US.md"
symbol: "TAK.US"
name: "Takeda Pharmaceutical Company Limited"
industry: "Pharmaceuticals"
---

# Takeda Pharmaceutical Company Limited (TAK.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [www.takeda.com](https://www.takeda.com) |

## Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, onco...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:14.000Z

**Overall: C (0.53)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 44 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.20% |  |
| Net Profit YoY | -44.45% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.21 |  |
| Dividend Ratio | 2.83% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 58.95B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 29.88B |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.50% | C |
| Profit Margin | 2.53% | C |
| Gross Margin | 66.34% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.20% | D |
| Net Profit YoY | -44.45% | D |
| Total Assets YoY | 2.23% | C |
| Net Assets YoY | 3.27% | C |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 3953.54% | A |
| OCF YoY | -0.20% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.29 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 50.39% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Takeda Pharmaceutical Company Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.50%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "2.53%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "66.34%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.20%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-44.45%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.23%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.27%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "3953.54%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-0.20%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.29",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "50.39%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Eli Lilly (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | Roche (US.RHHBY) | A | B | B | D | C | B |
| 04 | AstraZeneca (US.AZN) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 77.99 | 54/257 | 202.74 | 63.21 | 35.21 |
| PB | 1.21 | 56/257 | 1.03 | 0.98 | 0.94 |
| PS (TTM) | 1.97 | 52/257 | 1.60 | 1.55 | 1.49 |
| Dividend Yield | 2.83% | 13/257 | 3.67% | 3.34% | 1.86% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T05:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 3 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.66 |
| Highest Target | 19.98 |
| Lowest Target | 17.98 |

## References

- [Company Overview](https://longbridge.com/en/quote/TAK.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/TAK.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/TAK.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.